ADAP Adaptimmune Therapeutics plc

8.28
-0.19  -2%
Previous Close 8.47
Open 8.38
Price To book 3.38
Market Cap 774338040
Shares 93,519,087
Volume 677,757
Short Ratio 1.95
Av. Daily Volume 331,792

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171077973
  2. 8-K - Current report 171072877
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171003901
  4. 8-K - Current report 171002829
  5. 8-K - Current report 17978674

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated 2H 2017.
NY-ESO T-cell therapy
Synovial sarcoma - cancer
Further trials planned for 2H 2016
NY-ESO T-cell therapy
Ovarian cancer
Pivotal trial placed on clinical hold due to non-safety issues. Hold released November 2016. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy
Myxoid round cell liposarcoma (MRCLS)
Further trials planned for 1H 2017.
NY-ESO T-cell therapy
Myeloma
Phase 1/2 initiated November 2015. Data are due 2017.
NY-ESO T-cell therapy
Non-small cell lung cancer (NSCLC)

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171077973
  2. 8-K - Current report 171072877
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171003901
  4. 8-K - Current report 171002829
  5. 8-K - Current report 17978674
  6. 8-K - Current report 17945671
  7. 8-K - Current report 17923285
  8. 8-K - Current report 17893076
  9. 8-K - Current report 17890150
  10. 8-K - Current report 17873840